Meeting Diagnostic and Management Challenges

FACULTY

Michael A. Singer, MD

Seenu M. Hariprasad, MD

TARGET AUDIENCE

This educational activity is intended for ophthalmologists and ophthalmologists in residency or fellowship training.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be able to:

1. Define the screening, examination, laboratory analysis and imaging processes that drive accurate and detailed uveitis diagnoses.
2. Analyze the range of available and emerging treatment options for noninfectious and posterior noninfectious uveitis.
3. Explain how to make the best match of treatment and patient to decrease patient burden while optimizing treatment outcomes.
4. Review practice guidelines and options for adjustment in cases where treatment is intolerable or ineffective.
5. Use the knowledge of recent pivotal clinical trial outcomes by comparing and differentiatiating three critical technologies to manage posterior segment noninfectious uveitis: Ozurdex, Yutiq, and the CLS-TA injection. Phase 3 clinical trial data will be reviewed to close the educational gap.

EDITORIAL BOARD / FACULTY ADVISORS

Seenu Hariprasad, MD
Shui-Chin Lee Professor of Ophthalmology and Visual Science: Chief, Vitreoretinal Service: Director, Clinical Research: Director, Fellowship in Vitreoretinal Diseases and Surgery: The University of Chicago Medicine & Biological Sciences

Michael Singer, MD
Medical Center Ophthalmology Associates, San Antonio, TX

Tom Albini, MD
Bascom Palmer Eye Institute, Miami, FL

Technological Advances in Drug Delivery to Treat Noninfectious Posterior Segment Uveitis is jointly sponsored by Candeo Clinical/Science Communications, LLC, and the University of Florida College of Medicine. This publication is administered by an independent editorial board and supported by an unrestricted educational grant from ABBVIE.

Copyright 2020 Candeo Clinical/Science Communications, LLC. All rights reserved. Neither the university of Florida nor Candeo Clinical/Science Communications, LLC, assumes any responsibility for injury or damage to persons or property arising from the use of information or ideas contained in this publication.

CME REVIEWER

Gibran Khurshid, MD
Associate Professor, Department of Ophthalmology University of Florida College of Medicine

Technological Advances in Drug Delivery to Treat Noninfectious Posterior Segment Uveitis

STATEMENT OF NEED

#1 Identified Need: Need for accurate uveitis diagnoses with details regarding cause, site, onset, duration, and course

Desired Result: Rapid, accurate, and reproducible diagnosis

Learning Objective: Define the screening, examination, and laboratory analysis process that drives accurate and detailed uveitis diagnoses

#2 Identified Need: Selection of uveitis treatment based on cause and type

Desired Result: Selection of treatment options that are effective, safe, and appropriate for each type of uveitis patient

Learning Objective: Analyze the range of available and emerging treatment options for noninfectious and posterior noninfectious uveitis

#3 Identified Need: Create “best-match” treatment to minimize patient burden

Desired Result: Determine treatment that will best minimize patient burden and optimize outcomes

Learning Objective: Understand patient needs in selecting treatment to minimize patient burden while optimizing treatment outcomes

#4 Identified Need: Need for vigilant management to maximize chances of treatment success and reduce incidence of treatment-related adverse events

Desired Result: Improved health outcomes (inflammation management, vision restoration, alleviation of pain) with reduced risk and burden to patient

Learning Objective: To review practice guidelines and options for adjustment in cases where treatment is intolerable or ineffective

#5 Identified Need: Compare and differentiate three new technologies to manage posterior segment noninfectious uveitis

Desired Result: Improved health outcomes (inflammation management, vision restoration, alleviation of pain) with reduced risk and burden to patient

Learning Objective: Knowledge of recent pivotal clinical trial outcomes for new technologies to treat noninfectious posterior uveitis

OFF-LABEL USE STATEMENT

This work may discuss off-label uses of medications.

GENERAL INFORMATION

This CME activity is sponsored by the University of Florida College of Medicine and is supported by an unrestricted educational grant from ABBVIE.

The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. There is no fee to participate in this activity. In order to receive CME credit, participants should read the report, and then take the posttest. A score of 80% is required to qualify for CME credit. Estimated time to complete the activity is 60 minutes. On completion, take the test online at https://cme.ufl.edu/online-cme/tadd/

System requirements for this activity are: For PC users: Windows^® 2000, XP, 2003 Server, or Vista; Internet Explorer^® 6.0 or newer, or Mozilla^® Firefox^® 2.0 or newer (JavaScriptTM and JavaTM enabled). For Mac^® users: Mac OS^® X 10.4 (Tiger^®) or newer; SafariTM 3.0 or newer, Mozilla^® Firefox^® 2.0 or newer; (JavaScript™ and Java™ enabled).

Internet connection required: Cable modem, DSL, or better.

DATE OF ORIGINAL RELEASE

January 2021t. Approved for a period of 12 months.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Candeo Clinical/Science Communications, LLC. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY AND DISCLOSURE STATEMENTS

Seenu Hariprasad, MD Shui-Chin Lee Professor of Ophthalmology and Visual Science: Chief, Vitreoretinal Service: Director, Clinical Research: Director, Fellowship in Vitreoretinal Diseases and Surgery: The University of Chicago Medicine & Biological Sciences. Dr. Hariprasad is a consultant for Allergan, Novartis, and Alimera Sciences. He is on the Speaker’s Bureau for Allergan, Novartis, Alimera Sciences, Spark Therapeutics and Regeneron Pharmaceuticals.

Michael Singer, MD Medical Center Ophthalmology Associates, San Antonio, TX. Dr. Singer received Grant/Research support from Allergan, Aerie, Genentech, Regeneron, Optos, Kodiak and Senju. He is a consultant for Allergan, Aerie, Genentech. Dr. Singer serves on the Speaker’s Bureau for Allergan, Genentech, Regeneron, and Spark Therapeutics and is a Stock Shareholder in Nancoscope and Inflammasome.

Tom Albini, MD Bascom Palmer Eye Institute, Miami, FL. Dr. Albini is a consultant for Allegro Opthalmiocs, Allergan, Beaver, Visitec, Adverum Biotechnologies, Novartis, Santen Pharmaceuticals, Genentech, Valeant Pharmaceuticals, Notal Vision, Janssen Biotech, Regenex Bio and Clearside Biomedical.

Gibran Khurshid, MD, is an associate professor in the department of ophthalmology at the University of Florida College of Medicine. He states that in the past 12 months, he has not had a financial relationship with any commercial organization that produces, markets, resells, or distributes healthcare goods or services consumed by or used on patients relevant to this manuscript.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and professional development. The information presented in this activity is not meant to serve as a guideline for patient care. Procedures, medications, and other courses of diagnosis and treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, applicable manufacturer’s product information, and comparison with recommendations of other authorities.

COMMERCIAL SUPPORTERS

This activity is supported by an unrestricted educational grant from ABBVIE.